2023
Pharmacology of orismilast, a potent and selective PDE4 inhibitor
Silverberg J, French L, Warren R, Strober B, Kjøller K, Sommer M, Andres P, Felding J, Weiss A, Tutkunkardas D, Skak‐Nielsen T, Guttman E. Pharmacology of orismilast, a potent and selective PDE4 inhibitor. Journal Of The European Academy Of Dermatology And Venereology 2023, 37: 721-729. PMID: 36527389, DOI: 10.1111/jdv.18818.Peer-Reviewed Original ResearchConceptsChronic inflammatory skin diseasePeripheral blood mononuclear cellsEar thicknessPhosphodiesterase 4Clinical developmentBroad-spectrum anti-inflammatory activityPDE4 inhibitorsEx vivoHuman peripheral blood mononuclear cellsTumor necrosis factor αSecond-generation PDE4 inhibitorsEar skin inflammationWhole bloodMarkers of inflammationAnti-inflammatory effectsInflammatory skin diseasePro-inflammatory cytokinesBlood mononuclear cellsNovel treatment optionsNecrosis factor αPre-clinical modelsAnti-inflammatory activitySelective PDE4 inhibitorLong-term managementPBMC production
2014
Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities
Shlyankevich J, Mehta N, Krueger J, Strober B, Gudjonsson J, Qureshi A, Tebbey P, Kimball A. Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities. The American Journal Of Medicine 2014, 127: 1148-1153. PMID: 25149424, PMCID: PMC4259841, DOI: 10.1016/j.amjmed.2014.08.008.Peer-Reviewed Original Research
2008
Substantial Alterations of the Cutaneous Bacterial Biota in Psoriatic Lesions
Gao Z, Tseng C, Strober B, Pei Z, Blaser M. Substantial Alterations of the Cutaneous Bacterial Biota in Psoriatic Lesions. PLOS ONE 2008, 3: e2719. PMID: 18648509, PMCID: PMC2447873, DOI: 10.1371/journal.pone.0002719.Peer-Reviewed Original ResearchConceptsPsoriatic lesionsHealthy personsIdiopathic inflammatory disorderNormal skin samplesBroad-range PCRPsoriatic patientsInflammatory disordersUninvolved skinPsoriatic skinCutaneous samplesNormal skinPatientsLesion samplesNormal personsSubstantial alterationsLesionsPropionibacterium speciesSkin samplesPsoriasisSkinSpecies-level operational taxonomic unitsRDNA PCRAlterationsExtracted DNARange PCR
2007
Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review
Sterry W, Strober B, Menter A, Council O. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. British Journal Of Dermatology 2007, 157: 649-655. PMID: 17627791, DOI: 10.1111/j.1365-2133.2007.08068.x.Peer-Reviewed Original ResearchConceptsMore severe psoriasisStandard of careEvidence-based literatureCardiovascular comorbiditiesImportant healthcare issueSevere psoriasisSystemic inflammationYounger patientsMetabolic syndromeRheumatoid arthritisInsulin resistanceMyocardial infarctionPsoriasisTherapeutic implicationsObesityStrong associationComorbiditiesMedical specialtiesPatientsHealthcare issuesPathophysiologyHealth risksAssociationRiskDyslipidaemia